Cover Image

24 Thalidomide reverses latency of HIV-1 provirus

Saved in:

Bibliographic Details
Main Authors:	S. Samer (Author), T. Oshiro (Author), T. Vergara (Author), J. Gakinskas (Author), S. Tenori (Author), M.C. Sucupira (Author), A. Duarte (Author), R.S. Diaz (Author)
Format:	Book
Published:	Elsevier, 2016-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

20 Sirtuin1 inhibitor nicotinamide disrupts HIV-1 latency
by: S. Samer, et al.
Published: (2016)

Whole genome sequencing of single HIV provirus and its proviral integration site for the study of HIV latency
by: C. Sun, et al.
Published: (2017)

23 Understanding the effects of latency reversing agents on HIV RNA splicing: implications for latency reversal
by: T.M. Mota, et al.
Published: (2016)

Optimisation of Smac mimetics as HIV-1 latency reversing agents
by: L. Pache, et al.
Published: (2019)

Combinatorial latency reversal activity of inhibitor of apoptosis antagonists with mechanistically distinct classes of HIV latency reversal agents
by: Shane D. Falcinelli, et al.
Published: (2019)

Integration site-independent enhancement of latency reversal by HIV-1 Nef
by: X.T. Kuang, et al.
Published: (2017)

HIV latency reversal using designed PKC modulators
by: M.D. Marsden, et al.
Published: (2017)

9 LEDGIN-mediated inhibition of the IN-LEDGF/p75 interaction reduces provirus reactivation from latency
by: Zeger Debyser, et al.
Published: (2017)

Novel use of alprazolam as a potential HIV-1 latency reversing agent
by: W. Elbezanti, et al.
Published: (2017)

Croton oligandrus Pierre & Hutch (Euphorbiaceae) Extracts and Isolated Compounds Reverse HIV-1 Latency
by: Emade Nkwelle C, et al.
Published: (2024)

O3 Heme-arginate as a latency-reversing agent for HIV-1 cure
by: Michaela Madlenakova, et al.
Published: (2017)

HIV-1 proviruses which are integrated into cancer-related genes are inducible
by: A. Varabyou, et al.
Published: (2017)

38 Small molecule inhibitors of BAF; a new family of compounds in HIV-1 latency reversal
by: E. De Crignis, et al.
Published: (2016)

Cleavage and polyadenylation specific factor 6 is required for HIV latency reversal
by: Y. Zheng, et al.
Published: (2019)

Reactivation capacity by latency reversing agents ex vivo correlates with the size of the HIV-1 reservoir
by: Gilles Darcis, et al.
Published: (2016)

PP 5.4 - 00184 Optimization of Smac Mimetics as HIV-1 Latency Reversing Agents
by: L. Pache, et al.
Published: (2022)

Validation of an unbiased screen method for the identification of secondary fungal metabolites reversing HIV-1 latency
by: M. Stoszko, et al.
Published: (2017)

Approaches to discover latency-reversing agents
Published: (2015)

Developing and applying ultrasensitive p24 protein immunoassay for HIV latency
by: B.J. Howell, et al.
Published: (2015)

PP 1.33 - 00167 Integrated single-cell multi-omic profiling of HIV latency reversal
by: A. Manickam, et al.
Published: (2022)

Regulation of HIV-1 provirus and CD4+ T cell biology by transcriptional coregulators
by: B.C. Nikolai, et al.
Published: (2017)

PP 1.22 - 00120 Suppression of CD4+ T-cell-intrinsic immunity by HIV-1 latency-reversing HDACi
by: J. Kazmierski, et al.
Published: (2022)

Co-culture of T-cells with dendritic cells facilitates HIV latency in proliferating CD4+ T-cells: implications for the establishment and reversal of latency
by: N. Kumar, et al.
Published: (2015)

Synergistic HIV latency reversal from an in vitro screen of epigenetic and kinase inhibitors
by: D. Irlbeck, et al.
Published: (2017)

36 Dose-dependent effects of HDACi on T cell activation and HIV latency reversal
by: X.T. Kuang, et al.
Published: (2016)

Evaluation of HIV latency reversal using designed PKC modulators in humanized BLT mice
by: M.D. Marsden, et al.
Published: (2015)

No evidence of neuroaxonal injury following latency reversal with vorinostat and HIV-1 specific vaccination in the RIVER trial
by: J. Alagaratnam, et al.
Published: (2019)

Bioactive Compounds from <i>Euphorbia usambarica</i> Pax. with HIV-1 Latency Reversal Activity
by: Yu-Chi Tsai, et al.
Published: (2021)

Differential effects of HIV latency-reversing agents on T cell phenotype and function: implications for HIV cure
by: G. Clutton, et al.
Published: (2015)

Characterizing HIV expression of proviruses during ART in tissues and blood
by: W.R. McManus, et al.
Published: (2017)

Phorbol esters isolated from Croton megalobotrys reverse HIV latency ex vivo
by: I. Tietjen, et al.
Published: (2019)

Tissue-specific effects of latency-reversing agents on HIV transcriptional blocks in gut and blood
by: S. Telwatte, et al.
Published: (2019)

OP 2.8 - 00193 Enhancing PKC Modulator HIV Latency Reversing Agents
by: M. Marsden, et al.
Published: (2022)

Defining the Effects of PKC Modulator HIV Latency-Reversing Agents on Natural Killer Cells
by: Melanie Dimapasoc, et al.
Published: (2024)

The efficacy and tolerability of latency-reversing agents in reactivating the HIV-1 reservoir in clinical studies: a systematic review
by: Quinten Debrabander, et al.
Published: (2023)

Novel Histone Deacetylase Inhibitors and HIV-1 Latency-Reversing Agents Identified by Large-Scale Virtual Screening
by: Donya Naz Divsalar, et al.
Published: (2020)

O6 Reactivation capacity by latency reversing agents ex vivo correlates with the size of the HIV-1 reservoir
by: Gilles Darcis, et al.
Published: (2016)

PP 1.11 - 00075 Selective nuclear retention of spliced and unspliced HIV-1 mRNAs following latency reversal
by: E. Honeycutt, et al.
Published: (2022)

OP 1.7 - 00194 Potent latency reversal enables in-depth transcriptomic analysis of the translation-competent HIV-1 reservoir
by: M. Pardons, et al.
Published: (2022)

Towards achieving a state of reversible HIV-1 latency in primary monocyte-derived macrophages (MDM) by M1 polarization
by: G. Poli, et al.
Published: (2015)